Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  stage B adult primary liver cancer (BCLC)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 43 for your search:
Start Over
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 1112, NCI-2012-02057, NCT01730937
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ARQ197-A-U303, NCI-2013-00021, NCT01755767
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15982, NCI-2013-01156, 2012-003649-14, NCT01774344
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: XL184-309, NCI-2013-02092, NCT01908426
Gemcitabine Hydrochloride and Cisplatin with or without Radiation Therapy in Treating Patients with Localized Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GI001, NCI-2014-00849, PNRG-GI001_A01PAMDREVW01, PNRG-GI001_A02PAMDREVW01, NCT02200042
TRC105 and Sorafenib Tosylate in Treating Patients with Liver Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0102, NCI-2013-01477, 110102, 339029, P10766, NCT01306058
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Tivozanib in Treating Patients with Liver Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229112, NCI-2013-00756, NCT01835223
Radiolabeled Glass Beads, Radiofrequency Ablation, or Transarterial Chemoembolization in Treating Patients With Liver Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: NU09I2, NCI-2013-01386, IRB# STU00012339, NCT00956930
Temsirolimus and Sorafenib Tosylate in Treating Patients With Stage II-IV Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: 124511, NCI-2012-02021, NCT01687673
Sorafenib Tosylate and Combination Chemotherapy in Treating Patients with Advanced Liver Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-218, NCI-2013-00627, NCT01775501
Sorafenib Tosylate and Doxorubicin Hydrochloride in Treating Patients with Advanced Liver Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-259, NCI-2013-00867, NCT01840592
Doxorubicin-Eluting Beads in Treating Patients with Liver Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1306, NCI-2014-00341, CIR00005192, DEBDOX-M1, NA_00077927, NCT02007954
Chemoembolization with Doxorubicin Hydrochloride-Eluting Beads in Treating Patients with Liver Cancer Who Are Being Considered for Liver Transplant
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 124520, NCI-2015-00697, 082078, CC# 124520, DEB-TACE, UCSF CC#124520, NCT02147301
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PHP-HCC-201, NCI-2015-00604, NCT02406508
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NU 08I5, NCI-2009-01122, STU00007062, NCT00858429
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Sorafenib Tosylate and Vorinostat in Treating Patients With Advanced Liver Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-12122, NCI-2010-00185, NCT01075113
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A8081012, NCI-2012-01184, NCT01576406
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11105, NCI-2012-01040, CDR0000737061, NCI-2013-01545, P9008_A10PAMDREVW01, 9008, NCT01638533
Start Over